These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 18395781)

  • 1. Questioning the economic evaluation of omalizumab.
    Revicki D; Brown R; Dale P
    J Allergy Clin Immunol; 2008 Jun; 121(6):1514; author reply 1514-5. PubMed ID: 18395781
    [No Abstract]   [Full Text] [Related]  

  • 2. Revisiting the cost-effectiveness of omalizumab.
    Campbell JD; Spackman DE; Sullivan SD
    Allergy; 2007 Dec; 62(12):1469. PubMed ID: 17983382
    [No Abstract]   [Full Text] [Related]  

  • 3. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
    Sullivan SD; Turk F
    Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma.
    Brown R; Turk F; Dale P; Bousquet J
    Allergy; 2007 Feb; 62(2):149-53. PubMed ID: 17298423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab for severe allergic asthma: dollars and sense.
    Krishnan JA; Gould M
    J Allergy Clin Immunol; 2007 Nov; 120(5):1015-7. PubMed ID: 17983869
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-immunoglobulin E therapy with omalizumab for asthma.
    Hendeles L; Sorkness CA
    Ann Pharmacother; 2007 Sep; 41(9):1397-410. PubMed ID: 17698897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab: overview of pharmacology and efficacy in asthma.
    Ledford DK
    Expert Opin Biol Ther; 2009 Jul; 9(7):933-43. PubMed ID: 19527111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to Campbell, Spackman, Sullivan letter to Allergy.
    Brown R; Turk F; Dale P; Bousquet J
    Allergy; 2008 Jun; 63(6):783. PubMed ID: 18445194
    [No Abstract]   [Full Text] [Related]  

  • 9. [Omalizumab, an anti-IgE monoclonal antibody to treat severe asthma].
    Michils A; Sternon J
    J Pharm Belg; 2006; 61(3):83-7. PubMed ID: 17058881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy.
    Dal Negro RW; Pradelli L; Tognella S; Micheletto C; Iannazzo S
    Eur Ann Allergy Clin Immunol; 2011 Mar; 43(2):45-53. PubMed ID: 21608372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of omalizumab in a severe asthma clinic.
    Gibson PG; Taramarcaz P; McDonald VM
    Respirology; 2007 Nov; 12 Suppl 3():S35-44; discussion S45-7. PubMed ID: 17956518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technology evaluation: omalizumab, Genentech/Novartis/Tanox.
    Lazaar AL
    Curr Opin Mol Ther; 2003 Feb; 5(1):81-9. PubMed ID: 12669476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptom control and improved functioning: the effect of omalizumab on asthma-related quality of life (ARQL).
    Luskin AT; Kosinski M; Bresnahan BW; Ashby M; Wong DA
    J Asthma; 2005 Dec; 42(10):823-7. PubMed ID: 16393718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab for severe asthma?
    Drug Ther Bull; 2006 Nov; 44(11):86-8. PubMed ID: 17089921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pneumology. Anti-IgE antibodies in the treatment of asthma].
    Leuenberger P; Sauty A; Rochat T
    Rev Med Suisse; 2007 Jan; 3(93):56-9. PubMed ID: 17354662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab (Xolair) for treatment of asthma.
    Davydov L
    Am Fam Physician; 2005 Jan; 71(2):341-2. PubMed ID: 15686303
    [No Abstract]   [Full Text] [Related]  

  • 17. Lack of pretreatment cost-effectiveness and side effects of omalizumab versus prednisone/montelukast on tolerability of immunotherapy.
    Rosenberg JL
    J Allergy Clin Immunol; 2011 Feb; 127(2):548; author reply 548-9. PubMed ID: 21281877
    [No Abstract]   [Full Text] [Related]  

  • 18. Persistent severe asthma and aging: step-up therapy with omalizumab to improve control.
    Greenberger PA
    Ann Allergy Asthma Immunol; 2010 Dec; 105(6):408-10. PubMed ID: 21130375
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-IgE in severe persistent allergic asthma.
    Fox H
    Respirology; 2007 Nov; 12 Suppl 3():S22-8; discussion S45-7. PubMed ID: 17956516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.